GRPR and neoplasm: Further modifications of the GRPR-targeting probesare required to enable their use for targeted therapy, including radiotherapy.A comparison of the ABD-RM26 Gen 2A conjugate’s residence timein blood with ABD-fused conjugates efficiently used in a preclinicalmodel showed that toxicity to bone marrow should be acceptable inthe precondition that tumor uptake will be improved at least 1.5–2-fold.38,52